文献速递乳腺癌头颈与中枢神经肿瘤

优替帝隆联合贝伐珠单抗治疗ERBB2阴性转移性乳腺癌伴活动性脑转移:U-BOMB 2期非随机临床试验

Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2025-01-01

这项在中国5家医院开展的非随机2期临床试验纳入47例ERBB2阴性转移性乳腺癌伴活动性脑转移患者,接受优替帝隆联合贝伐珠单抗治疗。中枢神经系统客观缓解率为42.6%(95%CI 28.3%-57.8%),中位无进展生存期7.7个月,中位总生存期15.1个月,未发生严重或致死性不良事件。作者认为该方案具有潜在价值,需随机临床试验进一步验证。

要点

  • ERBB2阴性转移性乳腺癌伴活动性脑转移患者中,中枢神经系统客观缓解率为42.6%。
  • 中位无进展生存期7.7个月,中位中枢神经系统无进展生存期10.6个月,中位总生存期15.1个月。
  • 最常见≥3级治疗中出现的不良事件为淋巴细胞计数降低5例(10.6%)和白细胞计数降低3例(6.4%)。

核心结论

  • 作者认为,优替帝隆联合贝伐珠单抗对ERBB2阴性转移性乳腺癌伴活动性脑转移患者具有潜在治疗价值,需随机临床试验进一步验证。

研究设计与样本

  • 非随机临床试验,在中国5家医院开展。
  • 纳入47例ERBB2阴性转移性乳腺癌伴未经治疗或进展性脑转移的成年女性患者,中位年龄53岁(IQR 45-59岁)。
  • 35例脑转移未经治疗,12例脑转移在局部放疗后进展。
  • 患者每3周接受贝伐珠单抗(第1天15 mg/kg)和优替帝隆(第1-5天30 mg/m2),直至疾病进展或出现不可接受的毒性。
  • 入组时间2022年5月5日至2023年10月25日,数据截止日期2024年5月20日。

主要发现

  • 中枢神经系统客观缓解率按RECIST 1.1标准为42.6%(95%CI 28.3%-57.8%),按神经肿瘤脑转移疗效评估标准为40.4%(95%CI 26.4%-55.7%)。
  • 中位随访时间11.0个月(范围2.3-23.6个月)。
  • 中位无进展生存期7.7个月(95%CI 5.6-9.7),中位中枢神经系统无进展生存期10.6个月(95%CI 8.4个月至未达到),中位总生存期15.1个月(95%CI 12.0个月至未达到)。
  • 最常见的≥3级治疗中出现的不良事件为淋巴细胞计数降低5例(10.6%)和白细胞计数降低3例(6.4%)。
  • 未发生严重或致死性不良事件。

关键数值与推荐

  • 主要终点为按RECIST 1.1标准评估的中枢神经系统客观缓解率。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with ERBB2 (formerly HER2 or HER2/neu)-negative metastatic breast cancer (MBC) and brain metastases have poor prognosis, and effective treatment options are limited. OBJECTIVE: To investigate the activity and safety of utidelone plus bevacizumab in patients with ERBB2-negative MBC and active brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial was conducted at 5 hospitals in China. Adult patients with ERBB2-negative MBC who had untreated or progressive brain metastases were enrolled between May 5, 2022, and October 25, 2023. The data cutoff date was May 20, 2024; data were analyzed from September 15, 2022, to July 20, 2024. INTERVENTIONS: Patients received bevacizumab (15 mg/kg on day 1) and utidelone (30 mg/m2 on days 1-5) every 3 weeks until disease progression or unacceptable toxic effects. MAIN OUTCOMES AND MEASURES: The primary end point was central nervous system (CNS) objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. RESULTS: A total of 47 female patients (median age, 53 years [IQR, 45-59 years]) were recruited. Of these, 35 patients had untreated brain metastases and 12 had brain metastases that had progressed after local radiotherapy. The CNS ORR was 42.6% (95% CI, 28.3%-57.8%) per RECIST version 1.1 and 40.4% (95% CI, 26.4%-55.7%) per Response Assessment in Neuro-Oncology Brain Metastases criteria. The median follow-up duration was 11.0 months (range, 2.3-23.6 months). The median progression-free survival (PFS) was 7.7 months (95% CI, 5.6-9.7), median CNS-PFS was 10.6 months (95% CI, 8.4 months to not reached), and median overall survival was 15.1 months (95% CI, 12.0 months to not reached). The most common grade 3 or higher treatment-emergent adverse events were decreased lymphocyte count in 5 patients (10.6%) and decreased white blood cell count in 3 patients (6.4%). No serious or fatal adverse events occurred. CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest the potential of utidelone plus bevacizumab for the treatment of patients with ERBB2-negative MBC and active brain metastases. This treatment approach warrants further validation in a randomized clinical trial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05357417.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Yan M, Lv H, Liu X, et al. Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases: The U-BOMB Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. 2025. PMID: 40569584. doi:10.1001/jamaoncol.2025.1694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。